Management of familial melanoma

Lancet Oncology

Volumn 8, Issue 1, 2007, Pages 46-54

  Bishop, Julia Newton ^a   Harland, Mark ^a   Randerson Moor, Juliette ^a   Bishop, D Timothy ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 2A ISOFORM 4; PROTEIN P16INK4A;

AUSTRALIA; AUTOSOMAL DOMINANT INHERITANCE; CANCER RISK; CANCER SUSCEPTIBILITY; CORRELATION ANALYSIS; ENVIRONMENTAL FACTOR; EUROPE; EVIDENCE BASED MEDICINE; FAMILIAL CANCER; FAMILY HISTORY; GENETIC SUSCEPTIBILITY; GERM LINE; HUMAN; MELANOMA; MUTATIONAL ANALYSIS; NEVUS; PANCREAS CANCER; PEDIGREE ANALYSIS; PENETRANCE; PRIMARY PREVENTION; PRIORITY JOURNAL; RELATIVE; REVIEW; RISK ASSESSMENT; SECONDARY PREVENTION; SELF EXAMINATION; SUN EXPOSURE;

CYCLIN-DEPENDENT KINASE INHIBITOR P16; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MELANOMA; MUTATION; PEDIGREE; SKIN NEOPLASMS;

EID: 33845600809     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(06)71010-5     Document Type: Review

References (81)

1. Kaye F., and Harbour J. For whom the bell tolls: susceptibility to common adult cancers in retinoblastoma survivors. J Natl Cancer Inst 96 (2004) 342-343
2. Liede A., Karlan B., and Narod S. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol 22 (2004) 735-742
3. Potzsch C., Voigtlander T., and Lubbert M. p53 germline mutation in a patient with Li-Fraumeni syndrome and three metachronous malignancies. J Cancer Res Clin Oncol 128 (2002) 456-460
4. Anderson D., and Badzioch M. Hereditary cutaneous malignant melanoma: a 20-year family update. Anticancer Res 11 (1991) 433-438
5. Goldstein A., Chan M., Harland M., et al. Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J Med Genet (2006). published online Aug 11. DOI:10.1136/jmg.2006.043802
6. Monzon J., Liu L., Brill H., et al. CDKN2A mutations in multiple primary melanomas. N Engl J Med 338 (1998) 879-887
7. Valverde P., Healy E., Sikkink S., et al. The Asp84Glu variant of the melanocortin 1 receptor (MC1R) is associated with melanoma. Hum Mol Genet 5 (1996) 1663-1666
8. Bastiaens M., ter Huurne J., Gruis N., et al. The melanocortin-1-receptor gene is the major freckle gene. Hum Mol Genet 10 (2001) 1701-1708
9. Kamb A., Shattuck-Eidens D., Eeles R., et al. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 8 (1994) 22-26
10. Kamb A., Gruis N., Weaver-Feldhaus J., et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 264 (1994) 436-440
11. Zuo L., Weger J., Yang Q., et al. Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet 12 (1996) 97-99
12. Gillanders E., Hank Juo S., Holland E., et al. Localization of a novel melanoma susceptibility locus to 1p22. Am J Hum Genet 73 (2003) 301-313
13. Newton Bishop J., Harland M., and Bishop D. The genetics of melanoma. Br J Hosp Med 67 (2006) 299-304
14. Eliason M., Larson A., Florell S., et al. Population-based prevalence of CDKN2A mutations in Utah melanoma families. J Invest Dermatol 126 (2006) 660-666
15. Puig S., Malvehy J., Badenas C., et al. Role of the CDKN2A locus in patients with multiple primary melanomas. J Clin Oncol 23 (2005) 3043-3051
16. Lynch H., and Fusaro R. Pancreatic cancer and the familial atypical multiple mole melanoma (FAMMM) syndrome. Pancreas 6 (1991) 127-131
17. Bergman W., Watson P., de Jong J., et al. Systemic cancer and the FAMMM syndrome. Br J Cancer 61 (1990) 932-936
18. Goldstein A., and Tucker M. Familial melanoma and pancreatic cancer. N Engl J Med 334 (1996) 471
19. Goldstein A., Chan M., Harland M., et al. High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res 66 (2006) 9818-9828
20. Rutter J., Bromley C., Goldstein A., et al. Heterogeneity of risk for melanoma and pancreatic and digestive malignancies: a melanoma case-control study. Cancer 101 (2004) 2809-2816
21. Cannon-Albright L., Thomas A., Goldgar D., et al. Familiality of cancer in Utah. Cancer Res 54 (1994) 2378-2385
22. Kerber R., and O'Brien E. A cohort study of cancer risk in relation to family histories of cancer in the Utah population database. Cancer 103 (2005) 1906-1915
23. Chaudru V., Chompret A., Bressac-de Paillerets B., et al. Influence of genes, nevi, and sun sensitivity on melanoma risk in a family sample unselected by family history and in melanoma-prone families. J Natl Cancer Inst 96 (2004) 785-795
24. Hemminki K., Zhang H., and Czene K. Familial and attributable risks in cutaneous melanoma: effects of proband and age. J Invest Dermatol 120 (2003) 217-223
25. Begg C., Hummer A., Mujumdar U., et al. Familial aggregation of melanoma risks in a large population-based sample of melanoma cases. Cancer Causes Control 15 (2004) 957-965
26. Begg C., Orlow I., Hummer A., et al. Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample. J Natl Cancer Inst 97 (2005) 1507-1515
27. Gandini S., Sera F., Cattaruzza M., et al. Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer 41 (2005) 28-44
28. Gandini S., Sera F., Cattaruzza M., et al. Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur J Cancer 41 (2005) 2040-2059
29. Suzuki I., Cone R., Im S., et al. Binding of melanotropic hormones to the melanocortin receptor MC1R on human melanocytes stimulates proliferation and melanogenesis. Endocrinology 137 (1996) 1627-1633
30. Valverde P., Healy E., Jackson I., et al. Variants of the melanocyte stimulating hormone receptor gene are associated with red hair and fair skin in humans. Nat Genet 11 (1995) 328-330
31. Box N., Duffy D., Chen W., et al. MC1R genotype modifies risk of melanoma in families segregating CDKN2A mutations. Am J Hum Genet 69 (2001) 765-773
32. van der Velden P., Sandkuijl L., Bergman W., et al. Melanocortin-1 receptor variant R151C modifies melanoma risk in Dutch families with melanoma. Am J Hum Genet 69 (2001) 774-779
33. Easton D., Cox G., Macdonald A., and Ponder B. Genetic susceptibility to naevi: a twin study. Br J Cancer 64 (1991) 1164-1167
34. Zhu G., Duffy D., Eldridge A., et al. A major quantitative-trait locus for mole density is linked to the familial melanoma gene CDKN2A: a maximum-likelihood combined linkage and association analysis in twins and their sibs. Am J Hum Genet 65 (1999) 483-492
35. Wachsmuth R., Turner F., Barrett J., et al. The effect of sun exposure in determining nevus density in UK adolescent twins. J Invest Dermatol 124 (2005) 56-62
36. Falchi M., Spector T., Perks U., et al. Genome-wide search for nevus density shows linkage to two melanoma loci on chromosome 9 and identifies a new QTL on 5q31 in an adult twin cohort. Hum Mol Genet 15 (2006) 2975-2979
37. Newton Bishop J., and Bishop D. The genetics of susceptibility to cutaneous melanoma. Drugs Today (Barc) 41 (2005) 193-203
38. de Snoo F., and Hayward N. Cutaneous melanoma susceptibility and progression genes. Cancer Lett 230 (2005) 153-186
39. Fargnoli M., Argenziano G., Zalaudek I., and Peris K. High- and low-penetrance cutaneous melanoma susceptibility genes. Expert Rev Anticancer Ther 6 (2006) 657-670
40. In: Parkin D., Whelan S., Ferlay J., et al. (Eds). Cancer incidence in five continents. Volume VIII. IARC Scientific Publications, No 155 (2002), International Agency for Research on Cancer, Lyon
41. Gandini S., Sera F., Cattaruzza M., et al. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer 41 (2005) 45-60
42. Bishop D., Demenais F., Goldstein A., et al. Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst 94 (2002) 894-903
43. Siskind V., Aitken J., Green A., and Martin N. Sun exposure and interaction with family history in risk of melanoma, Queensland, Australia. Int J Cancer 97 (2002) 90-95
44. Berwick M., Armstrong B., Ben-Porat L., et al. Sun exposure and mortality from melanoma. J Natl Cancer Inst 97 (2005) 195-199
45. Garland C., and Garland F. Do sunlight and vitamin D reduce the likelihood of colon cancer?. Int J Epidemiol 9 (1980) 227-231
46. Holick M. High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc 81 (2006) 353-373
47. Holick M. Vitamin D: its role in cancer prevention and treatment. Prog Biophys Mol Biol 92 (2006) 49-59
48. Chen T., and Holick M. Vitamin D and prostate cancer prevention and treatment. Trends Endocrinol Metab 14 (2003) 423-430
49. Reichrath J., and Querings K. No evidence for reduced 25-hydroxyvitamin D serum level in melanoma patients. Cancer Causes Control 15 (2004) 97-98
50. Halsall J., Osborne J., Potter L., et al. A novel polymorphism in the 1A promoter region of the vitamin D receptor is associated with altered susceptibilty and prognosis in malignant melanoma. Br J Cancer 91 (2004) 765-770
51. Hutchinson P., Osborne J., Lear J., et al. Vitamin D receptor polymorphisms are associated with altered prognosis in patients with malignant melanoma. Clin Cancer Res 6 (2000) 498-504
52. Kricker A., and Armstrong B. Does sunlight have a beneficial influence on certain cancers?. Prog Biophys Mol Biol 92 (2006) 132-139
53. Newton J., Bataille V., Griffiths K., et al. How common is the atypical mole syndrome phenotype in apparently sporadic melanoma?. J Am Acad Dermatol 29 (1993) 989-996
54. Bataille V., Newton Bishop J., Sasieni P., et al. Risk of cutaneous melanoma in relation to the numbers, types and sites of naevi: a case-control study. Br J Cancer 73 (1996) 1605-1611
55. Schafer T., Merkl J., Klemm E., et al. The epidemiology of nevi and signs of skin aging in the adult general population: results of the KORA-survey 2000. J Invest Dermatol 126 (2006) 1490-1496
56. Stierner U., Augustsson A., Rosdahl I., and Suurkula M. Regional distribution of common and dysplastic naevi in relation to melanoma site and sun exposure. A case-control study. Melanoma Res 1 (1992) 367-375
57. Ruas M., and Peters G. The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta 1378 (1998) F115-F177
58. Sviderskaya E., Hill S., Evans-Whipp T., et al. p16(Ink4a) in melanocyte senescence and differentiation. J Natl Cancer Inst 94 (2002) 446-454
59. Bennett D. Human melanocyte senescence and melanoma susceptibility genes. Oncogene 22 (2003) 3063-3069
60. Florell S., Meyer L., Boucher K., et al. Longitudinal assessment of the nevus phenotype in a melanoma kindred. J Invest Dermatol 123 (2004) 576-582
61. Newton Bishop J., Harland M., Wachsmuth R., et al. Genotype/phenotype and penetrance studies in melanoma families with germline CDKN2A mutations. J Invest Dermatol 114 (2000) 28-33
62. Bergman W., Gruis N., and Frants R. The Dutch FAMMM family material: clinical and genetic data. Cytogenet Cell Genet 59 (1992) 161-164
63. Wachsmuth R., Harland M., and Bishop J. The atypical-mole syndrome and predisposition to melanoma. N Engl J Med 339 (1998) 348-349
64. Riedijk S., de Snoo F., van Dijk S., et al. Hereditary melanoma and predictive genetic testing: why not?. Psychooncology 14 (2005) 738-745
65. Kefford R., Newton Bishop J., Bergman W., and Tucker M. Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: a consensus statement of the Melanoma Genetics Consortium. J Clin Oncol 17 (1999) 3245-3251
66. Kefford R., Bishop J., Tucker M., et al. Genetic testing for melanoma. Lancet Oncol 3 (2002) 653-654
67. Azzarello L., Dessureault S., and Jacobsen P. Sun-protective behavior among individuals with a family history of melanoma. Cancer Epidemiol Biomarkers Prev 15 (2006) 142-145
68. Holick M. Vitamin D: a millenium perspective. J Cell Biochem 88 (2003) 296-307
69. Newton Bishop J., Taylor T., Potts H., et al. Sun protective behaviours in families at increased risk of melanoma. J Invest Dermatol 126 (2006) (in press)
70. Feit N., Dusza S., and Marghoob A. Melanomas detected with the aid of total cutaneous photography. Br J Dermatol 150 (2004) 706-714
71. Parker J., Florell S., Alexander A., et al. Pancreatic carcinoma surveillance in patients with familial melanoma. Arch Dermatol 139 (2003) 1019-1025
72. Goldstein A. Familial melanoma, pancreatic cancer and germline CDKN2A mutations. Hum Mutat 23 (2004) 630
73. Nielsen K., Ingvar C., Masback A., et al. Melanoma and nonmelanoma skin cancer in patients with multiple tumours-evidence for new syndromes in a population-based study. Br J Dermatol 150 (2004) 531-536
74. Mantelli M., Barile M., Ciotti P., et al. High prevalence of the G101W germline mutation in the CDKN2A (P16(ink4a)) gene in 62 Italian malignant melanoma families. Am J Med Genet 107 (2002) 214-221
75. Randerson-Moor J., Harland M., Williams S., et al. A germline deletion of p14(ARF) but not CDKN2A in a melanoma-neural system tumour syndrome family. Hum Mol Genet 10 (2001) 55-62
76. Hewitt C., Lee Wu C., Evans G., et al. Germline mutation of ARF in a melanoma kindred. Hum Mol Genet 11 (2002) 1273-1279
77. Rizos H., Puig S., Badenas C., et al. A melanoma-associated germline mutation in exon 1 beta inactivates p14ARF. Oncogene 20 (2001) 5543-5547
78. Harland M., Taylor C., Chambers P., et al. A mutation hotspot at the p14ARF splice site. Oncogene 24 (2005) 4604-4608
79. Hruban R., Canto M., and Yeo C. Prevention of pancreatic cancer and strategies for management of familial pancreatic cancer. Dig Dis 19 (2001) 76-84
80. Rulyak S., Kimmey M., Veenstra D., and Brentnall T. Cost-effectiveness of pancreatic cancer screening in familial pancreatic cancer kindreds. Gastrointest Endosc 57 (2003) 23-29
81. Tredaniel J., Boffetta P., Buiatti E., et al. Tobacco smoking and gastric cancer: review and meta-analysis. Int J Cancer 72 (1997) 565-573